| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma
|
Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.; Lu L.-C.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:16:08Z |
β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Lu L.-C.;Yu-Yun Shao;Lee Y.-H.;Hsieh M.-S.;Hsiao C.-H.;Lin H.-H.;Kao H.-F.;Ma Y.-Y.;Yen F.-C.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; YU-YUN SHAO; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C. |
| 臺大學術典藏 |
2020-04-10T12:16:07Z |
Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy
|
Lu L.-C.;Yu-Yun Shao;Chan S.-Y.;Hsu C.-H.;Cheng A.-L.; Lu L.-C.; YU-YUN SHAO; Chan S.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:06Z |
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
|
Yen F.-C.; Hsu C.-H.; Cheng A.-L.; YU-YUN SHAO; Wu C.-H.; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yu-Yun Shao;Wu C.-H.;Lu L.-C.;Chan S.-Y.;Ma Y.-Y.;Yen F.-C.;Hsu C.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:03Z |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials
|
Chan S.-Y.; Shau W.-Y.; YU-YUN SHAO; Yu-Yun Shao;Shau W.-Y.;Chan S.-Y.;Lu L.-C.;Hsu C.-H.;Cheng A.-L.; Lu L.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma
|
Lin H.-H.; Feng W.-C.; Lu L.-C.; YU-YUN SHAO; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study
|
Yeh Y.-C.; Chen P.-J.; Lu L.-C.;Chen P.-J.;Yeh Y.-C.;Hsu C.-H.;Chen H.-M.;Lai M.-S.;Yu-Yun Shao;Cheng A.-L.; Lu L.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; YU-YUN SHAO; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:56Z |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Lu L.-C.;Lee Y.-H.;Chang C.-J.;Shun C.-T.;Fang C.-Y.;Yu-Yun Shao;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; YU-YUN SHAO; Liu T.-H.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:15:55Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.;Yu-Yun Shao;Lu L.-C.;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; YU-YUN SHAO; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:54Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.; Yen C.-J.; Chao Y.; Lu L.-C.; Hsu C.; YU-YUN SHAO; Lu L.-C.;Hsu C.;Yu-Yun Shao;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Hsu C.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:53Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Yu-Yun Shao;Liu T.-H.;Hsu C.;Lu L.-C.;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-09T09:42:28Z |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials
|
Shao, Y.-Y.; Shau, W.-Y.; Chan, S.-Y.; Lu, L.-C.; Hsu, C.-H.; Cheng, A.-L. |
| 臺大學術典藏 |
2020-03-05T08:04:11Z |
β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma
|
Lu L.-C.; Shao Y.-Y.; Lee Y.-H.; MIN-SHU HSIEH; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-03-02T06:40:17Z |
Product mix planning in semiconductor manufacturing
|
Hong, I.H.; Chou, Y.-C.; Kuo, C.-Y.; Lu, L.-C.; YON-CHUN CHOU |
| 臺大學術典藏 |
2020-03-02T06:40:17Z |
A tool portfolio planning methodology for semiconductor wafer fabs
|
You, R.-C.; Weng, C.-R.; Chou, Y.-C.; Wu, H.H.; Lu, L.-C.; YON-CHUN CHOU |
| 臺大學術典藏 |
2020-02-14T02:49:54Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; Hsu C.; WEN-FANG CHENG; Lin Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-02-06T05:22:05Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Cheng A.-L.; Yeh K.-H.; WEN-FANG CHENG; Lin Y.-L.; Hsu C.; Hsu C.-H.; Shao Y.-Y.; Lu L.-C.; Yeh K.-H.; Cheng A.-L.; Lin Y.-L.; WEN-FANG CHENG; Hsu C.; Yeh K.-H.;Cheng A.-L.;Lin Y.-L.;WEN-FANG CHENG;Hsu C.;Hsu C.-H.;Shao Y.-Y.;Lu L.-C.; Lu L.-C.; Shao Y.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2020 |
Tocilizumab for severe COVID-19: a systematic review and meta-analysis
|
Lu L.-C.; Chang S.-P.; Lan S.-H.; Lai C.-C.; Huang H.-T.; PO-REN HSUEH |
| 臺大學術典藏 |
2019 |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Lu L.-C.; Shen Y.-C.; Chiun Hsu; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.; Liu T.-H.; Shao Y.-Y. |
| 臺大學術典藏 |
2019 |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Chang C.-J.; Lee Y.-H.; Lu L.-C.;Lee Y.-H.;Chang C.-J.;Shun C.-T.;Fang C.-Y.;Shao Y.-Y.;Liu T.-H.;Cheng A.-L.;Chih-Hung Hsu; Lu L.-C.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; Cheng A.-L.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2019 |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; CHIUN HSU; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2018-09-10T18:06:23Z |
Targeting tumor-infiltrating Ly6G+myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma
|
Chang, C.-J.;Yang, Y.-H.;Chiu, C.-J.;Lu, L.-C.;Liao, C.-C.;Liang, C.-W.;Hsu, C.-H.;Cheng, A.-L.; ANN-LII CHENG |
| 臺大學術典藏 |
2018-09-10T14:51:33Z |
Molecular Epidemiology of Japanese Encephalitis Virus in Mosquitoes in Taiwan during 2005–2012
|
Su, C.-L. ; Yang, C.-F. ; Teng, H.-J. ; Lu, L.-C. ; Lin, C. ; Tsai, K.-H. ; Chen, Y.-Y. ; Chen, L.-Y. ; Chang, S.-F. ; Shu, P.-Y.; KUN-HSIEN TSAI |
| 臺大學術典藏 |
2018-09-10T07:03:13Z |
Linearization of a two-axis MEMS scanner driven by vertical comb-drive actuators
|
Tsai, J.-C.; Lu, L.-C.; Hsu, W.-C.; Sun, C.-W.; Wu, M.C.; JUI-CHE TSAI |
| 臺大學術典藏 |
2018 |
Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma
|
Chang C.-J.;Yao-Hsu Yang;Chiu C.-J.;Lu L.-C.;Liao C.-C.;Liang C.-W.;Hsu C.-H.;Cheng A.-L.; Chang C.-J.; YAO-HSU YANG; Chiu C.-J.; Lu L.-C.; Liao C.-C.; Liang C.-W.; Hsu C.-H.; Cheng A.-L. |
